Eloxatin
Neoadjuvant Treatment
Shanghai Minimally Invasive Surgery CenterPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Neoadjuvant Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Center, Korea | Phase 2 | CCC |
Cetuximab Shanghai Minimally Invasive Surgery Center | Phase 2 | CCC |
Catequentinib Shanghai Minimally Invasive Surgery Center | Phase 2 | CCC |
Capecitabine Shanghai Minimally Invasive Surgery Center | Phase 2 | CCC |
Pembrolizumab Peking University Cancer Hospital & Institute | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Eloxatin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →